Market Access News | pharmaphorum

News

Novartis hits back at Entresto selection on Medicare list

Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations,

News

GB first to approve Roche's subcutaneous Tecentriq

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has become the first regulator to approve Roche's subcutaneous (SC) formulation of cancer immunotherapy

News

BMS grabs key approval for Reblozyl in MDS

Bristol-Myers Squibb's blockbuster aspirations for Reblozyl have been given a boost by the FDA after it approved the drug as a first-line treatment for anaemia in patients

News

One year on, ABPI asks why IMF hasn't funded any drugs

The Innovative Medicines Fund (IMF), set up in the UK last year to fast-track NHS access to promising new drugs, still hasn't provided any funding for a new medicine, and

News

First Tysabri biosimilar cleared by FDA for MS

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overc

News